WBB Securities’ Brozak to Co-Present at 2012 Biodefense Vaccines and Therapeutics Summit
Summit will provide progress of various countermeasures from the Public Health Emergency Medical Countermeasures Enterprise Review and how they will impact biodefense
For Immediate Release
June 6, 2012
SAN DIEGO, CA– WBB Securities Managing Partner and President, Stephen G. Brozak, will be co-presenting the Global Landscape & Markets in Anti-Infectives and the Implications of Drug Resistance and Emerging Infectious Diseases discussion at the 2012 BioDefense Vaccines and Therapeutics Summit. The discussion will begin on June 7, 2012 at 1:05 pm at the Almas Temple Club in Washington DC.
About WBB Securities
WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients. The firm also maintains an investment banking and equity research practice focused exclusively in the life sciences niche. www.wbbsec.com
About BioDefense Vaccines and Therapeutics Conference
The 10th Annual Biodefense Vaccines & Therapeutics conference, June 6-7, 2012, will provide progress-to-date of the various medical countermeasures (MCM) initiatives from the PHEMCE Review and how they will impact the biodefense and the broader public health sector. Senior government representatives will detail the many initiatives, how these initiatives are helping to incentivize private sector and academia participation, and what opportunities are being created to drive growth in medical countermeasures for CBRN and emerging infectious diseases threats. Moreover, the conference will provide insights into how emerging infectious threats and public health concerns will shape BARDA’s use of its Special Reserve Fund and the potential impacts on the biodefense industry.